CagriSema Update: Early Responders Lost More Weight, but New Analysis Is Not a Treatment Rule
New REDEFINE 1 analyses examine early weight-loss patterns and patient-reported function. The 25.4% result applies to a selected on-treatment subgroup, not everyone receiving CagriSema.
For research use only. Not for human consumption.